The high cost of Emend (aprepitant) is primarily attributed to its status as a branded pharmaceutical with patent protection [1]. The development of new drugs like Emend involves significant investment in research, clinical trials, and regulatory processes, which manufacturers recoup through pricing [2].
When Does Emend's Patent Protection End?
The original patent for aprepitant expired in 2020 [1]. However, manufacturers can sometimes extend market exclusivity through additional patents or regulatory exclusivities. Information regarding specific patent expiries and potential market exclusivities for Emend can be found on DrugPatentWatch.com [1].
What Are the Alternatives to Emend?
Several antiemetic medications are available to manage chemotherapy-induced nausea and vomiting (CINV). These include other NK1 receptor antagonists, as well as drugs from different classes such as 5-HT3 receptor antagonists (e.g., ondansetron, granisetron), corticosteroids (e.g., dexamethasone), and dopamine antagonists [3]. The choice of treatment often depends on the specific type of chemotherapy and individual patient factors.
How Does Emend Work?
Emend is a neurokinin-1 (NK1) receptor antagonist. It works by blocking the action of substance P, a neurotransmitter involved in the vomiting reflex, particularly in the central nervous system [2]. This mechanism helps to prevent both acute and delayed nausea and vomiting associated with chemotherapy [2].
Who Manufactures Emend?
Emend was originally developed by Merck & Co., Inc. [4].
What Clinical Data Supports Emend's Use?
Clinical trials have demonstrated Emend's efficacy in combination with other antiemetic agents for preventing CINV [2]. Studies have shown significant reductions in the incidence of nausea and vomiting when Emend is included in the treatment regimen [2].
What Are Patient Concerns About Emend?
Patients may experience side effects from Emend, though the drug is generally well-tolerated [5]. Common side effects reported include fatigue, hiccups, and loss of appetite [5]. Patients should discuss any concerns or potential side effects with their healthcare provider.